Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia

Journal of the National Cancer Institute

Volumn 89, Issue 17, 1997, Pages 1285-1293

  Kadish, Anna S ^a   Ho, Gloria Y F ^a   Burk, Robert D ^a   Wang, Yuexian ^a   Romney, Seymour L ^a   Ledwidge, Richard ^a   Angeletti, Ruth H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY RESPONSE; ARTICLE; CANCER GRADING; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE RESPONSE; LYMPHOPROLIFERATIVE DISEASE; OUTCOMES RESEARCH; PAPILLOMA VIRUS; STEM CELL; VIRUS INFECTION; WART VIRUS;

EID: 0030752702     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.17.1285     Document Type: Article

References (42)

1. Morrison EA, Ho GY, Vermund SH, Goldberg GL, Kadish AS, Kelley KF. et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer 1991;49:6-13.
2. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
3. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
4. Gram IT, Austin H, Stalsberg H. Cigarette smoking and the incidence of cervical intraepithelial neoplasia, grade III, and cancer of the cervix uteri. Am J Epidemiol 1992;135:341-6.
5. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62.
6. Ho GY, Burk RD, Fleming I, Klein RS. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994;56:788-92.
7. Klein RS, Ho GY, Vermund SH, Fleming I, Burk RD. Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. J Infect Dis 1994;170:1404-9.
8. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
9. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A 1991;88:110-4.
10. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
11. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schnewies KE, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-704.
12. Krchnak V, Vagner J, Suchankova A, Krcmar M, Ritterova L, Vonka V. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 1990;71:2719-24.
13. Mandelson MT, Jenison SA, Sherman KJ, Valentine JM, McKnight B, Daling JR, et al. The association of human papillomavirus antibodies with cervical cancer risk. Cancer Epidemiol Biomarkers Prev 1992;1:281-6.
14. Muller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, et al. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 1992;187:508-14.
15. Altmann A, Jochmus-Kudielka I, Frank R, Gausepohl H, Moebius H, Gissmann L, et al. Definition of imnunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur J Cancer 1992;28: 326-33.
16. Cubie HA, Norval M, Crawford L, Banks L, Crook T. Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia. Epidemiol Infect 1989;103:625-32.
17. Tarpey I, Stacey S, Hickling J, Birley HD, Renton A, McIndoe A, et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. Immunology 1994;81:222-7.
18. Kadish AS, Romney SL. Ledwidge R. Tindle R. Fernando GJ. Zee SY. et al. Cell-mediated immune response to E7 peptides of human papillomavirus (HPV) type 16 are dependent on HPV type infecting the cervix whereas serologic reactivity is not type-specific. J Gen Virol 1994;75:2277-84.
19. de Gruijl TD. Bontkes HJ. Stukart MJ. Walboomers JM. Remmink AJ. Verheijen RH, et al. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996;77:2183-91.
20. Luxton JC, Rowe AJ. Cridland JC. Coletart T. Wilson P. Shepherd PS. Proliferate T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996;77:1585-93.
21. Tsukui T, Hildesheim A, Schiffman MH, Lucci J 3rd. Contois D. Lawler P. et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996;56:3967-74.
22. Richart RM. Cervical intraepithelial neoplasia: a review. Pathol Ann 1973; 8:301-28.
23. Tabbara S, Saleh AD, Andersen WA, Barber SR, Taylor PT, Crum CP. The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic, and viral correlates. Obstel Gyneeol 1992;79:338-46.
24. Manos MM, Ting T, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
25. Tachezy R, Van Ranst MA, Cruz Y, Burk RD. Analysis of short novel human papillomavirus sequences. Biochem Biophys Res Commun 1994; 204:820-7.
26. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Green CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
27. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174:679-89.
28. Pennington MW, Dunn BM. Peptide synthesis protocols. Meth Molec Biol 1994;35:1-321.
29. Grant GA. Synthetic peptides: a user's guide. New York: W. H. Freeman, 1992:1-382.
30. Russell J, Gee P, Liu SM, Angeletti RH. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994; 135:337-12.
31. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
32. Liang KY, Zeger SL. Longtitudinal data analysis using generalized linear models. Biometnca 1986;73:13-22.
33. Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, et al. Effects of beta carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gyneeol Oncol 1997;65:483-92.
34. Comerford SA, McCance DJ, Dougan G, Tite JP. Identification of T-and B-cell epitopes of the E7 protein of human papillomavirus type 16. J Virol 1991;65:4681-90.
35. Stacey SN, Eklund C, Jordan D, Smith NK, Stern PL, Dillner J, et al. Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies [published erratum appears in Oncogene 1994; 9:1515]. Oncogene 1994;9:635-45.
36. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, et al. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 1994;75:157-64.
37. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci U S A 1992;89:7871-5.
38. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152: 3904-12.
39. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14: 115-20.
40. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
41. Shepherd PS, Rowe AJ, Cridland JC, Coletart T, Wilson P, Luxton JC. Proliterative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J Gen Virol 1996;77:593-602.
42. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89: 245-50.